IDEAYA Biosciences Balance Sheet Health
Financial Health criteria checks 6/6
IDEAYA Biosciences has a total shareholder equity of $935.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $961.5M and $26.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$698.77m |
| Equity | US$935.31m |
| Total liabilities | US$26.22m |
| Total assets | US$961.53m |
Recent financial health updates
Is IDEAYA Biosciences (NASDAQ:IDYA) A Risky Investment?
Feb 22
Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation
Oct 03IDEAYA Biosciences (NASDAQ:IDYA) Is In A Good Position To Deliver On Growth Plans
Jul 04We're Not Very Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate
Mar 10Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation
Nov 04We Think IDEAYA Biosciences (NASDAQ:IDYA) Can Afford To Drive Business Growth
Apr 12Recent updates
Is IDEAYA Biosciences (NASDAQ:IDYA) A Risky Investment?
Feb 22Ideaya Biosciences: A Strong Bet In Targeted Oncology
Feb 16Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week
Nov 09Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation
Oct 03IDEAYA Biosciences (NASDAQ:IDYA) Is In A Good Position To Deliver On Growth Plans
Jul 04We're Not Very Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate
Mar 10Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation
Nov 04Ideaya Biosciences: Prospects Rebound With Updated Uveal Melanoma Data
Oct 06Ideaya Biosciences slides 8.5% aftermarket on $80M stock offering
Sep 14Ideaya wins first milestone in GSK deal as cancer drug reaches clinical trials
Aug 29Analysts Have Just Cut Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Revenue Estimates By 6.2%
Aug 25IDEAYA Biosciences GAAP EPS of -$0.57 misses by $0.05, revenue of $11.34M beats by $4.75M
Aug 15IDEAYA, Amgen in clinical trial deal for small molecule cancer agent
Jul 27Ideaya: Next 6 Months Critical For Precision Oncology Biotech
Jun 16Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week
May 16We Think IDEAYA Biosciences (NASDAQ:IDYA) Can Afford To Drive Business Growth
Apr 12IDEAYA Biosciences EPS beats by $0.01, misses on revenue
May 10Financial Position Analysis
Short Term Liabilities: IDYA's short term assets ($709.4M) exceed its short term liabilities ($25.0M).
Long Term Liabilities: IDYA's short term assets ($709.4M) exceed its long term liabilities ($1.3M).
Debt to Equity History and Analysis
Debt Level: IDYA is debt free.
Reducing Debt: IDYA had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IDYA has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: IDYA has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 33% each year